Organic compounds -- part of the class 532-570 series patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 536  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14:  |  |  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Organic compounds -- part of the class 532-570 series

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
12/04/2014 > 10 patent applications in 5 patent subcategories.

20140357848 - Crystalline 4'-epidaunorubicin hydrochloride and use thereof: 4′-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4′-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected from C1 and C2 halogenated solvents and mixtures thereof, (b) solvent B selected from C1-C5 straight... Agent:

20140357850 - Nucleic acid encoding antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9): Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen... Agent:

20140357851 - Nucleic acid encoding antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9): Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen... Agent:

20140357849 - Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease: The present invention relates to compositions and methods for preparing splice variants of TNFalpha receptor (TNFR) in vivo or in vitro, and the resulting TNFR protein variants. Such variants may be prepared by controlling the splicing of pre-mRNA molecules and regulating protein expression with splice switching oligonucleotides or splice switching... Agent: Santaris Pharma A/s

20140357852 - Nucleic acid encoding antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9): Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen... Agent:

20140357853 - Nucleic acid encoding antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9): Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen... Agent:

20140357854 - Nucleic acid encoding antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9): Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen... Agent:

20140357856 - Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry: The present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3′-endo conformational geometry (3′-endo regions) or DNA like having southern or C2′-endo/O4′-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in... Agent: Isis Pharmaceuticals, Inc.

20140357855 - Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure: The invention relates to oligonucleotides for inducing skipping of exon 53 of the dystrophin gene. The invention also relates to methods of inducing exon 53 skipping using the oligonucleotides.... Agent: Academisch Ziekenhuis Leiden

20140357857 - Porous structures of microbial-derived cellulose for in vivo implantation: This invention relates to polysaccharide materials and more particularly to microbial-derived cellulose having the porosity and containing pores of the desired size making it suitable for cellular infiltration during implantation and other desirable properties for medical and surgical applications. The invention also relates to the use of porous microbial-derived cellulose... Agent:

  
11/27/2014 > 10 patent applications in 8 patent subcategories.

20140350230 - Multi-functional nucleic acid-based anti-cancer drug capable of targeting and therapy, method for preparing same and anti-cancer composition comprising same: The present invention relates to a multi-functional nucleic acid-based anti-cancer drug in which the anti-cancer drug is physically bound to a linear nucleic acid having a thiol group at 5′ terminal thereof and then gold nanoparticles and aptamers are chemically bound. The present invention also relates to a method for... Agent: Research & Business Foundation Sungkyunkwan University

20140350231 - Method of preparing deoxyribofuranose compounds: The invention relates to methods for making deoxyribofuranose compounds such as compound (2) which are useful intermediates in the preparation of pharmaceutical compounds such as 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and the like.... Agent:

20140350232 - Sirna conjugate and preparation method thereof: Provided are an siRNA-polymer conjugate, and a method for preparing the same, and more specifically, to a hybrid conjugate formed by covalently bonding siRNA and a polymeric compound for improving the in vivo stability of siRNA, and to a preparation method of the hybrid conjugate. The conjugate of the present... Agent: Bioneer Corporation

20140350233 - Sirna conjugate and preparation method thereof: Provided are an siRNA-polymer conjugate, and a method for preparing the same, and more specifically, to a hybrid conjugate formed by covalently bonding siRNA and a polymeric compound for improving the in vivo stability of siRNA, and to a preparation method of the hybrid conjugate. The conjugate of the present... Agent: Bioneer Corporation

20140350235 - In situ oligonucleotide synthesis on a paramagnetic support: A novel method for attaching oligonucleotides to a paramagnetic solid support is disclosed. Conventional methods of attachment require that oligonucleotides be pre-synthesized with specific end modifications, which is laborious and expensive. Instead, we attached oligonucleotides to paramagnetic beads by direct synthesis of the oligonucleotides on the surface of the beads.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20140350234 - Nucleosides and oligonucleotides for studies on reversal of cytotoxic and mutagenic damage of dna and as diagnostics tools: The present invention is directed to n-alkylated synthetic nucleosides of high regiospecific purity and oligonucleotides that can be utilized for studies on reversal of cytotoxic and mutagenic DNA damage, and as diagnostic tools.... Agent: Chemgenes Corporation

20140350236 - Method of preparing cationic starch using ultrahigh pressure: Disclosed is a method of preparing cationic starch. The method includes preparing a starch suspension containing a cationization agent; performing ultrahigh pressure treatment on the starch suspension; and obtaining cationic starch from the starch suspension subjected to ultrahigh pressure treatment.... Agent:

20140350237 - Photo-crosslinked gellan gum-based hydrogels: methods and uses thereof: s

20140350238 - Composition of novel carbohydrate drug for treatment of human diseases: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked... Agent:

20140350239 - Pharmaceutical composition for relieving pain: p

  
11/20/2014 > 14 patent applications in 12 patent subcategories.

20140343261 - Sorbent comprising on its surface an aliphatic unit having an anionic or deprotonizable group for the purification of organic molecules: The present invention relates to a sorbent comprising a solid support material, the surface of which comprises a residue of a general formula (I), wherein the residue is attached via a covalent single bond to a functional group on the surface of either the bulk solid support material itself or... Agent:

20140343262 - Methods for purifying steviol glycosides and uses of the same: Methods for purifying steviol glycosides, including Rebaudioside X, are provided herein. Sweetener and sweetened containing Rebaudioside X are also provided herein. Methods of improving the flavor and/or temporal profile of sweetenable compositions, such as beverages, are also provided.... Agent:

20140343263 - Method to recover bioactive compounds: The invention relates to a process for separating bioactive compounds obtained from vegetable materials. The invention also relates to a process for extracting bioactive compounds from vegetable material.... Agent: Langtech International Pty., Limited

20140343266 - Antisense nucleic acids: e

20140343265 - Methods for manipulating biomolecules: In some embodiments, the present teachings provide compositions, systems, methods and kits for generating a population of nucleic acid fragments. In some embodiments, nucleic acids can be fragmented enzymatically. For example, methods for generating a population of nucleic acid fragments can include a nucleic acid nicking reaction. In one embodiment,... Agent:

20140343264 - Neutral nucleic acid ligands: The invention generally relates to isolated nucleic acid ligands that are neutral under physiological conditions.... Agent: Vivonics, Inc.

20140343267 - Il-17 binding proteins: Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.... Agent: Abbvie Inc.

20140343268 - Methods for purifying nucleic acids and devices thereof: A nucleic acid purification device includes a housing and an adapter operatively attached to the housing. The adapter is configured to receive at least one well plate which includes a plurality of wells for receiving contents including at least a sample and a plurality of paramagnetic particles. The device also... Agent: Health Diagnostic Laboratory, Inc.

20140343269 - Method of purifying low molecular weight hyaluronic acid or cationized hyaluronic acid via precipitation from aqueous solution by addition of alcohol or acetone followed by ph adjustment: Provided a method of producing a purified hyaluronic acid type which comprises adding a water-soluble organic medium to a solution which comprises a hyaluronic acid type having an average molecular weight of 400 to 100,000 and has a pH of 3 or less to obtain a suspension, and adjusting a... Agent:

20140343270 - Regeneration of cellulose: A method for regeneration of a cellulose containing material, comprises the steps: a) exposing the cellulose containing material to oxygen with an alkali aqueous solution at a pH of at least 9, and a temperature of at least 20° C., b) dispersing the cellulose containing material in the alkali aqueous... Agent:

20140343271 - Regioselectively substituted cellulose esters produced in a tetraalkylammonium alkylphosphate ionic liquid process and products produced therefrom: This invention relates a cellulose solution comprising cellulose and at least one tetraalkylammonium alkylphosphate and processes to produce the cellulose solution. Another aspect of this invention relates to shaped articles prepared from a cellulose solution comprising cellulose and at least one tetraalkylammonium alkylphosphate. Another embodiment of this invention relates to... Agent: Eastman Chemical Company

20140343272 - Preparation method of acetylated cellulose ether, and acetylated cellulose ether prepared thereby: Disclosed are a method of preparing acetylated cellulose ether, and acetylated cellulose ether prepared thereby. Here, the disclosed method of preparing the acetylated cellulose ether includes dissolving acetylated cellulose ether in an organic solvent to obtain a mixture comprising a solution of the acetylated cellulose ether; removing an insoluble component... Agent: Samsung Fine Chemicals Co., Ltd.

20140343273 - Preparation of enzymatically hydrolyzed starch: The present invention pertains to methods for preparing enzymatically hydrolyzed starch for use as a stabilizing agent that include the steps of first gelatinizing a starch and next, hydrolyzing the gelatinized starch with an enzyme having endo-hydrolytic activity. The present invention also pertains to the resulting enzymatically hydrolyzed starch for... Agent: Cargill, Incorporated

20140343274 - Preparation method of cationic dextrin: Disclosed herein is a method of preparing a cationic dextrin, including: performing cationization reaction by adding a cationization agent to dextrin.... Agent: University-industry Cooperation Group Of Kyung Hee University

  
11/13/2014 > 4 patent applications in 3 patent subcategories.

20140336369 - Process for preparing heparinoids and intermediates useful in the synthesis thereof: Processes are disclosed for the synthesis of the Factor Xa anticoagulant fondaparinux and related compounds. Protected pentasaccharide intermediates and efficient and scalable processes for the industrial scale production of fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions are provided.... Agent: Apicore US LLC

20140336370 - Oligomeric compounds and compositions for use in modulation of small non-coding rnas: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment... Agent: Regulus Therapeutics Inc.

20140336371 - Sirna molecule for inhibiting growth of melanin and application thereof: Provided is a double-chain siRNA molecule targeting a microphthalmia-associated transcription factor MITF coding gene. A sense strand of the siRNA molecule has a sequence of SEQ ID NO: 3 and an anti-sense strand has a sequence of SEQ ID NO: 4, and the anti-sense strand specifically binds to mRNA of... Agent:

20140336372 - Dna extraction from seeds using osmoticum: The invention broadly relates to methods of fragmenting seed by use of mechanical devices such as crushing pins or other crushing devices with a preconditioned hard seed. Methods of preconditioning the seeds to soften the seed for more effective fragmentation which are adapted to enhance extracted DNA yields and/or DNA... Agent: Syngenta Participations Ag

Previous industry: Organic compounds -- part of the class 532-570 series
Next industry: Organic compounds -- part of the class 532-570 series


######

RSS FEED for 20141204: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Organic compounds -- part of the class 532-570 series patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Organic compounds -- part of the class 532-570 series patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Organic compounds -- part of the class 532-570 series patents we recommend signing up for free keyword monitoring by email.



Results in 0.44289 seconds

PATENT INFO